Read transcripts of debates in both Houses
Produced by Commons Library, Lords Library and Parliamentary Office Science and Technology
Search for Members by name, postcode, constituency and party
Learn about their experience, knowledge and interests
Celebrating people who have made Parliament a positive, inclusive working environment
Four staff networks for people to discuss and consider issues.
2018 marks 100 years since some women, and all men, could vote. Find out how you can join in
Sign up for the Your Parliament newsletter to find out how you can get involved
Take a tour of Parliament and enjoy a delicious afternoon tea by the River Thames
See some of the sights you’ll encounter on a tour of Parliament
Book a school visit, classroom workshop or teacher-training session
Access videos, worksheets, lesson plans and games
Follow this EDM by:
That this House welcomes the decision by the National Institute for Health and Care Excellence (NICE) to recommend the Duchenne muscular dystrophy treatment, Translarna, for funding by NHS England, as a result of a Managed Access Agreement; notes that Translarna is the first ever approved drug to treat an underlying genetic cause of Duchenne muscular dystrophy; recognises the tireless campaigning by patients and families throughout the NHS England and NICE processes calling for access to Translarna; acknowledges the vital role that Muscular Dystrophy UK and Action Duchenne have played as patient organisation stakeholders during the NICE assessment process; further recognises the role of other charities in pressing for access to Translarna; further notes with concern the announcement by the Scottish Medicines Consortium to recommend that Translarna not be approved for funding by NHS Scotland; and calls on NHS England to shorten implementation from three months so that the drug is available as quickly as possible.
Total number of signatures: 28
Showing 28 out of 28